Cancer immunotherapy | The PD-L1 pathway

The role of the immune system is to protect the body from foreign invaders. In responding to cancer, T cells play a central role in the immune system. Programmed death ligand 1 (PD-L1) is one of the inhibitory ligands that, under normal conditions, help maintain immune homeostasis. In many cancers, however, PD-L1 can help tumour cells evade immune system surveillance.
To learn more about Roche’s commitment to cancer immunotherapy, visit www.roche.com/cancer-immunothe.... To learn more about our cancer immunotherapy research, visit global.researchcancerimmunothe....
Subscribe to our KZbin channel now: kzbin.info?su...
Get in touch with us:
www.roche.com/
/ rochecareers
/ roche
/ roche
Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
For more information and insights visit: www.roche.com/

[@JMSouchak]

Excellent and quick PD-1 explanation! Thank you!

[@braveheart4280]

best way to express this topic is in this video... thanks

[@roche]

Thank you for your kinds words. That's so good to hear. We appreciate you taking the time to share it with us! Have a nice day ahead!

[@user-bm5zz1rb3j]

Need more people so spread this video more

[@jhonatanpiffer676]

That's a very good explanation! Congratulations

[@sopaanshukla468]

My mother has PDL1 rating of 20. The Assay used to test PDL1 is DAKO-22c3. Can any one tell me how well the medicine - Pembrolizumab - is effective to damp PDL1 interaction woth T- Cells

[@ahmedibrahim-te4sx]

What can we done to solve the problem of PD overexpression ?

[@mikeletterst9882]

Great question, monoclonal antibodies against PD-1 have been developed that prevent the binding of PD-1 to PD-L1; this block T cell inhibition, thereby restoring the cytotoxic response and promoting apoptosis of tumor cells. Anti-PD1 therapy is used in advanced melanoma and certain types of lung cancer. Unfortunately, the clinical effectiveness of PD-1 immune blockade is still uncertain.

[@jwbbccp]

Mike Letterst Great answer! Moreover, I believe there is additional concern that PD-1 blockade may significantly increase the risk for autoimmune disease, hence why it is only being used in cases of advanced melanomas and similarly “untreatable” fatal conditions... basically, when the increased risk of lifelong autoimmune disease is outweighed by the higher probability of death.

[@khouse1554]

Jon Wood yea and at the end of the day because of that patients can develop resistance to immunotherapy. Need to figure out ways to indirectly also downregulate PD-L1 on cancer cell to improve this blockade

[@rosylindt7255]

@@mikeletterst9882 It is also important to note that patients response depends on other factors such as the tumo microenvironment, the tumor mutation profile and it is also specific to individual patient (this part being the key mystery). This therapy has been used to treat PD1+ tumors but with poor response but other tumors such as melanoma and lung cancer are responding well to these therapies

[@taniabelerique2454]

Traduz em português?

[@patriciaantunes19]

How to cite this video?

[@Burrdmizzle]

You and me both😂

[@lucilabascur1862]

Traducir al español porfavor gracias.

[@ppack217]

Lucila Riquelme iii